Hormonal
Tirzepatide administration significantly reduces body weight in overweight and obese individuals (BMI ≥28 kg/m²) compared to control, with the magnitude of weight loss being dose-dependent.
If you have a BMI of 28 or higher, Tirzepatide is a clinically proven option for significant weight loss. It works by mimicking hormones that regulate blood sugar and appetite. You take it as a once-weekly injection, starting at a low dose (2.5mg) and increasing to 5mg, 10mg, or 15mg depending on your response. Expect some gastrointestinal side effects like nausea or diarrhea, especially at higher doses, but most people tolerate it well. The higher the dose, the more weight you tend to lose.
The pooled findings showed that Tirzepatide vs control significantly reduced body weight (mean difference (MD): -7.38, 95% confidence interval (CI): -13.66 to -1.09)... The results of subgroup analysis showed that the trend of weight loss is dose-dependent (5mg: MD: -6.87... 10 mg: MD: -9.62... 15mg: MD: -11.00).
Why this rating
Meta-analysis of 11 randomized controlled trials with 11,710 participants.
Source
Efficacy and Safety of Tirzepatide in Overweight and Obese Individuals: A Meta-Analysis of Randomized Controlled Trials
Liya Fu et al. · Medical Research Frontiers · 2026
DOI 10.57237/j.mrf.2025.04.001
More from this paper
- Tirzepatide significantly reduces HbA1c levels in individuals with Type 2 Diabetes, with the effect being dose-dependent.Strong
- Tirzepatide use is associated with a significantly increased incidence of adverse reactions, particularly gastrointestinal issues like nausea and diarrhea, which are dose-dependent.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →